Vinzolidine

N/A

Report date: 2026/01/28 15:58:52

Base Information

Drug NameVinzolidine

Drug Alias NameVZLVinzolidinaVinzolidinummethyl (13S,15R,17S)-13-[(1'R,5S,9'R,11'R,12'R,19'R)-11'-acetyloxy-3-(2-chloroethyl)-12'-ethyl-5'-methoxy-8'-methyl-2,4-dioxospiro[1,3-oxazolidine-5,10'-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene]-4'-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylateLY104208 +[6]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTubulin polymerisation inhibitors

TargetsTubulin

Therapy Area/IndicationsLymphoma, Non-HodgkinHodgkin DiseaseNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesEli Lilly And Company

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEli Lilly And Company The University Of Arizona

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-HodgkinHodgkin DiseaseNeoplasms

Other Information

ATC CodeN/A